{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "# from xml.etree import ElementTree\n",
    "\n",
    "# Define the base URL for the search API\n",
    "base_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "# Define the query parameters\n",
    "query_params = {\n",
    "    \"format\": \"json\",  # Search expression\n",
    "    \"query.cond\": \"Neuropathic pain\",  # Fields to return\n",
    "    \"query.locn\": \"United States of America\",  # Minimum rank\n",
    "    \"pageSize\" : 500\n",
    "}\n",
    "\n",
    "# Make the API request\n",
    "response = requests.get(base_url, params=query_params)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "json_response = response.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "10\n"
     ]
    }
   ],
   "source": [
    "studies = json_response[\"studies\"]\n",
    "print(len(studies))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NF0g5JKOlfcvxgc\n"
     ]
    }
   ],
   "source": [
    "print(json_response[\"nextPageToken\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['protocolSection', 'resultsSection', 'derivedSection', 'hasResults'])"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "studies[0].keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'identificationModule': {'nctId': 'NCT01701362',\n",
       "  'orgStudyIdInfo': {'id': 'A0081279'},\n",
       "  'secondaryIdInfos': [{'id': '2012-003304-12', 'type': 'EUDRACT_NUMBER'}],\n",
       "  'organization': {'fullName': 'Pfizer', 'class': 'INDUSTRY'},\n",
       "  'briefTitle': 'Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain',\n",
       "  'officialTitle': 'A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain'},\n",
       " 'statusModule': {'statusVerifiedDate': '2017-04',\n",
       "  'overallStatus': 'COMPLETED',\n",
       "  'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "  'startDateStruct': {'date': '2012-10'},\n",
       "  'primaryCompletionDateStruct': {'date': '2015-08', 'type': 'ACTUAL'},\n",
       "  'completionDateStruct': {'date': '2015-08', 'type': 'ACTUAL'},\n",
       "  'studyFirstSubmitDate': '2012-10-03',\n",
       "  'studyFirstSubmitQcDate': '2012-10-03',\n",
       "  'studyFirstPostDateStruct': {'date': '2012-10-05', 'type': 'ESTIMATED'},\n",
       "  'resultsFirstSubmitDate': '2016-07-20',\n",
       "  'resultsFirstSubmitQcDate': '2017-05-04',\n",
       "  'resultsFirstPostDateStruct': {'date': '2017-06-07', 'type': 'ACTUAL'},\n",
       "  'lastUpdateSubmitDate': '2021-01-26',\n",
       "  'lastUpdatePostDateStruct': {'date': '2021-01-28', 'type': 'ACTUAL'}},\n",
       " 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "  'leadSponsor': {'name': \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\",\n",
       "   'class': 'INDUSTRY'}},\n",
       " 'oversightModule': {'oversightHasDmc': True},\n",
       " 'descriptionModule': {'briefSummary': 'This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.'},\n",
       " 'conditionsModule': {'conditions': ['Neuropathic Pain'],\n",
       "  'keywords': ['post-traumatic peripheral neuropathic pain']},\n",
       " 'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "  'phases': ['PHASE3'],\n",
       "  'designInfo': {'allocation': 'RANDOMIZED',\n",
       "   'interventionModel': 'PARALLEL',\n",
       "   'primaryPurpose': 'TREATMENT',\n",
       "   'maskingInfo': {'masking': 'DOUBLE',\n",
       "    'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "  'enrollmentInfo': {'count': 542, 'type': 'ACTUAL'}},\n",
       " 'armsInterventionsModule': {'armGroups': [{'label': 'pregabalin',\n",
       "    'type': 'ACTIVE_COMPARATOR',\n",
       "    'interventionNames': ['Drug: pregabalin']},\n",
       "   {'label': 'placebo',\n",
       "    'type': 'PLACEBO_COMPARATOR',\n",
       "    'interventionNames': ['Drug: placebo']}],\n",
       "  'interventions': [{'type': 'DRUG',\n",
       "    'name': 'pregabalin',\n",
       "    'description': 'capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization',\n",
       "    'armGroupLabels': ['pregabalin'],\n",
       "    'otherNames': ['Lyrica, PD-144723']},\n",
       "   {'type': 'DRUG',\n",
       "    'name': 'placebo',\n",
       "    'description': 'capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization',\n",
       "    'armGroupLabels': ['placebo']}]},\n",
       " 'outcomesModule': {'primaryOutcomes': [{'measure': 'Baseline Mean Pain Score',\n",
       "    'description': 'This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 (\"no pain\") to 10 (\"worst possible pain\"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.',\n",
       "    'timeFrame': 'Baseline'},\n",
       "   {'measure': 'Change From Baseline to Week 15 in Weekly Mean Pain Score',\n",
       "    'description': 'This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 (\"no pain\") to 10 (\"worst possible pain\"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.',\n",
       "    'timeFrame': 'up to Week 15'}],\n",
       "  'secondaryOutcomes': [{'measure': 'Patient Global Impression of Change (PGIC) at Week 15',\n",
       "    'description': \"A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale.\",\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS)',\n",
       "    'description': 'This is an 11-point NRS ranging from 0 (\"pain does not interfere with sleep\") to 10 (\"pain completely interferes with sleep\" \\\\[unable to sleep due to pain\\\\]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context.\\n\\nNote: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week \\'n\\' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7\\\\*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings.\\n\\n\"Overall\" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks.',\n",
       "    'timeFrame': 'up to Week 15'},\n",
       "   {'measure': 'Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])',\n",
       "    'description': 'A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome.',\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Change From Baseline in Pain Interference Index (BPI-sf)',\n",
       "    'description': 'BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation.\\n\\nIt consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes).\\n\\nThe BPI-sf pain interference index was calculated as average of the seven individual pain interference scores.',\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores',\n",
       "    'description': \"A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale.\",\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.',\n",
       "    'description': 'MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores.\\n\\nSleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement.\\n\\nSleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement.\\n\\nQuantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement.\\n\\nOptimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.',\n",
       "    'timeFrame': 'Baseline'},\n",
       "   {'measure': 'Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.',\n",
       "    'description': 'MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores.\\n\\nSleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement.\\n\\nSleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement.\\n\\nQuantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement.\\n\\nOptimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.',\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Percentage of Participants in MOS-SS With Optimal Sleep Status.',\n",
       "    'description': 'MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable.',\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%.',\n",
       "    'description': \"Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\\\\*(n-1) to Day 1+7\\\\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.\",\n",
       "    'timeFrame': 'Week 15'},\n",
       "   {'measure': 'Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50%',\n",
       "    'description': \"Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\\\\*(n-1) to Day 1+7\\\\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.\",\n",
       "    'timeFrame': 'Week 15'}]},\n",
       " 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Subjects must have chronic peripheral neuropathic pain present for than 6 months after a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.\\n* Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone in order to complete the IVRS assessments each day, perform telephone visits and complete all required assessments/forms.\\n* Subjects must have sufficient post-traumatic neuropathic pain at screening and baseline.\\n\\nExclusion Criteria:\\n\\n* Subjects with neuropathic pain due to diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), HIV, trigeminal neuralgia (TGN), carpal tunnel syndrome (CTS) or with central neuropathic pain (for example, due to spinal cord injury) or with Complex Regional Pain Syndrome (CRPS, Type I or Type II).\\n* Subjects with other pain that may confound assessment or self-evaluation of the peripheral neuropathic pain.\\n* Subjects who have failed pregabalin treatment due to lack of efficacy with an adequate course of therapy at doses greater than or equal to 150 mg/day, who have previously participated in a pregabalin clinical trial or who have been treated with pregabalin at any time during the 6 month period prior to screening.\\n* Subjects with epilepsy; pernicious anemia; hematological illnesses; known HIV infection; any clinically unstable cardiovascular (including a myocardial infarction \\\\[heart attack\\\\] in the 3 months prior to screening), hematological, autoimmune, endocrine, renal, hepatic (including chronic hepatitis B, hepatitis B within the 3 months prior to screening) respiratory, or gastrointestinal disease; symptomatic peripheral vascular disease including intermittent claudication; uncontrolled diabetes mellitus; untreated hypothyroidism.\\n* Subjects with a diagnosis of DSM-IV TR Axis I disorder (including, for example, schizophrenia, bipolar disorder) with the exceptions of Generalized Anxiety Disorder (GAD) or major depression that is clinically stable.\\n* Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment.\\n* Use of prohibited medications in the absence of appropriate washout periods.',\n",
       "  'healthyVolunteers': False,\n",
       "  'sex': 'ALL',\n",
       "  'minimumAge': '18 Years',\n",
       "  'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       " 'contactsLocationsModule': {'overallOfficials': [{'name': 'Pfizer CT.gov Call Center',\n",
       "    'affiliation': 'Pfizer',\n",
       "    'role': 'STUDY_DIRECTOR'}],\n",
       "  'locations': [{'facility': 'Tennesse Valley Pain Consultants',\n",
       "    'city': 'Huntsville',\n",
       "    'state': 'Alabama',\n",
       "    'zip': '35801',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.7304, 'lon': -86.58594}},\n",
       "   {'facility': 'Dedicated Clinical Research',\n",
       "    'city': 'Goodyear',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85395',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.43532, 'lon': -112.35821}},\n",
       "   {'facility': 'Elite Clinical Studies, LLC',\n",
       "    'city': 'Phoenix',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85018',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "   {'facility': 'HOPE Research Institute',\n",
       "    'city': 'Phoenix',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85018',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "   {'facility': 'The Pain Center of Arizona',\n",
       "    'city': 'Phoenix',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85018',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "   {'facility': 'Arizona Research Center',\n",
       "    'city': 'Phoenix',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85023',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "   {'facility': 'The Pain Center of Arizona',\n",
       "    'city': 'Phoenix',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85027',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "   {'facility': 'Neuromuscular Research Center',\n",
       "    'city': 'Phoenix',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85028',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "   {'facility': 'Quality of Life Medical & Research Centers, LLC',\n",
       "    'city': 'Tucson',\n",
       "    'state': 'Arizona',\n",
       "    'zip': '85712',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.22174, 'lon': -110.92648}},\n",
       "   {'facility': 'Advanced Rx Clinical Research',\n",
       "    'city': 'Artesia',\n",
       "    'state': 'California',\n",
       "    'zip': '90701',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.86585, 'lon': -118.08312}},\n",
       "   {'facility': 'Behavioral Research Specialists, LLC',\n",
       "    'city': 'Glendale',\n",
       "    'state': 'California',\n",
       "    'zip': '91206',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.14251, 'lon': -118.25508}},\n",
       "   {'facility': 'NervePro Medical Corp.',\n",
       "    'city': 'Irvine',\n",
       "    'state': 'California',\n",
       "    'zip': '92618',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.66946, 'lon': -117.82311}},\n",
       "   {'facility': 'University of California, Irvine',\n",
       "    'city': 'Irvine',\n",
       "    'state': 'California',\n",
       "    'zip': '92697',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.66946, 'lon': -117.82311}},\n",
       "   {'facility': 'Clinical and Translational Research Institute',\n",
       "    'city': 'La Jolla',\n",
       "    'state': 'California',\n",
       "    'zip': '92093',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.84727, 'lon': -117.2742}},\n",
       "   {'facility': 'Alliance Research Centers',\n",
       "    'city': 'Laguna Hills',\n",
       "    'state': 'California',\n",
       "    'zip': '92653',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.61252, 'lon': -117.71283}},\n",
       "   {'facility': 'South Orange County Surgical Medical Group',\n",
       "    'city': 'Laguna Hills',\n",
       "    'state': 'California',\n",
       "    'zip': '92653',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.61252, 'lon': -117.71283}},\n",
       "   {'facility': 'Center For United Research, Inc.',\n",
       "    'city': 'Lakewood',\n",
       "    'state': 'California',\n",
       "    'zip': '90805',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.85363, 'lon': -118.13396}},\n",
       "   {'facility': 'University of Southern California',\n",
       "    'city': 'Los Angeles',\n",
       "    'state': 'California',\n",
       "    'zip': '90033',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.05223, 'lon': -118.24368}},\n",
       "   {'facility': 'USC I.D.S. Pharmacy',\n",
       "    'city': 'Los Angeles',\n",
       "    'state': 'California',\n",
       "    'zip': '90089',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.05223, 'lon': -118.24368}},\n",
       "   {'facility': 'Samaritan Center for Medical Research',\n",
       "    'city': 'Los Gatos',\n",
       "    'state': 'California',\n",
       "    'zip': '95032',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 37.22661, 'lon': -121.97468}},\n",
       "   {'facility': 'North County Clinical Research',\n",
       "    'city': 'Oceanside',\n",
       "    'state': 'California',\n",
       "    'zip': '92056',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.19587, 'lon': -117.37948}},\n",
       "   {'facility': 'Allied Clinical Research',\n",
       "    'city': 'Roseville',\n",
       "    'state': 'California',\n",
       "    'zip': '95661',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.75212, 'lon': -121.28801}},\n",
       "   {'facility': 'Northern California Research',\n",
       "    'city': 'Sacramento',\n",
       "    'state': 'California',\n",
       "    'zip': '95821',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.58157, 'lon': -121.4944}},\n",
       "   {'facility': 'Diablo Clinical Research, Inc.',\n",
       "    'city': 'Walnut Creek',\n",
       "    'state': 'California',\n",
       "    'zip': '94598',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 37.90631, 'lon': -122.06496}},\n",
       "   {'facility': 'Elite Clinical Trials, Inc.',\n",
       "    'city': 'Wildomar',\n",
       "    'state': 'California',\n",
       "    'zip': '92595',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.59891, 'lon': -117.28004}},\n",
       "   {'facility': 'Colorado Clinic',\n",
       "    'city': 'Boulder',\n",
       "    'state': 'Colorado',\n",
       "    'zip': '80301',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 40.01499, 'lon': -105.27055}},\n",
       "   {'facility': 'Mountain View Clinical Research Inc.',\n",
       "    'city': 'Denver',\n",
       "    'state': 'Colorado',\n",
       "    'zip': '80209',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 39.73915, 'lon': -104.9847}},\n",
       "   {'facility': \"St. Luke's Medical Clinic\",\n",
       "    'city': 'Fort Collins',\n",
       "    'state': 'Colorado',\n",
       "    'zip': '80525',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 40.58526, 'lon': -105.08442}},\n",
       "   {'facility': 'Investigational Drug Services, The George Washington University Medical Center',\n",
       "    'city': 'Washington',\n",
       "    'state': 'District of Columbia',\n",
       "    'zip': '20037',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.89511, 'lon': -77.03637}},\n",
       "   {'facility': 'The George Washington University Medical Center (Department of Neurology)',\n",
       "    'city': 'Washington',\n",
       "    'state': 'District of Columbia',\n",
       "    'zip': '20037',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.89511, 'lon': -77.03637}},\n",
       "   {'facility': 'The George Washington University Medical Center',\n",
       "    'city': 'Washington',\n",
       "    'state': 'District of Columbia',\n",
       "    'zip': '20037',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.89511, 'lon': -77.03637}},\n",
       "   {'facility': 'Orthopedic Research Institute',\n",
       "    'city': 'Boynton Beach',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33472',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 26.52535, 'lon': -80.06643}},\n",
       "   {'facility': 'Advance Medical Research',\n",
       "    'city': 'Clearwater',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33756',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 27.96585, 'lon': -82.8001}},\n",
       "   {'facility': 'Innovative Research of West Florida',\n",
       "    'city': 'Clearwater',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33756',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 27.96585, 'lon': -82.8001}},\n",
       "   {'facility': 'Aga Clinical Trials',\n",
       "    'city': 'Hialeah',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33012',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.8576, 'lon': -80.27811}},\n",
       "   {'facility': 'Health Care Family Rehab & Research Center',\n",
       "    'city': 'Hialeah',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33012',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.8576, 'lon': -80.27811}},\n",
       "   {'facility': 'Research in Miami, Inc.',\n",
       "    'city': 'Hialeah',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33013',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.8576, 'lon': -80.27811}},\n",
       "   {'facility': 'Homestead Medical Research , Inc.',\n",
       "    'city': 'Homestead',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33030',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.46872, 'lon': -80.47756}},\n",
       "   {'facility': 'AMPM Research Clinic',\n",
       "    'city': 'Miami Gardens',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33169',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.94298, 'lon': -80.24452}},\n",
       "   {'facility': 'San Marcus Research Clinic, Inc.',\n",
       "    'city': 'Miami',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33015',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.77427, 'lon': -80.19366}},\n",
       "   {'facility': 'Advanced Pharma CR, LLC',\n",
       "    'city': 'Miami',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33136',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.77427, 'lon': -80.19366}},\n",
       "   {'facility': 'Florida International Research Center',\n",
       "    'city': 'Miami',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33173',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.77427, 'lon': -80.19366}},\n",
       "   {'facility': 'Kendall South Medical Center, Inc.',\n",
       "    'city': 'Miami',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33185',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 25.77427, 'lon': -80.19366}},\n",
       "   {'facility': 'Compass Research, LLC',\n",
       "    'city': 'Orlando',\n",
       "    'state': 'Florida',\n",
       "    'zip': '32806',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 28.53834, 'lon': -81.37924}},\n",
       "   {'facility': 'A-One Family Practice',\n",
       "    'city': 'Ormond Beach',\n",
       "    'state': 'Florida',\n",
       "    'zip': '32174',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.28581, 'lon': -81.05589}},\n",
       "   {'facility': 'Aba Family Medicine, LLC',\n",
       "    'city': 'Ormond Beach',\n",
       "    'state': 'Florida',\n",
       "    'zip': '32174',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.28581, 'lon': -81.05589}},\n",
       "   {'facility': 'Ribo Research, LLC dba Peninsula Resarch',\n",
       "    'city': 'Ormond Beach',\n",
       "    'state': 'Florida',\n",
       "    'zip': '32174',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.28581, 'lon': -81.05589}},\n",
       "   {'facility': 'Comprehensive Pain Care of South Florida',\n",
       "    'city': 'Royal Palm Beach',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33411',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 26.7084, 'lon': -80.2306}},\n",
       "   {'facility': 'Sarasota Pain Medicine Research',\n",
       "    'city': 'Sarasota',\n",
       "    'state': 'Florida',\n",
       "    'zip': '34238',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 27.33643, 'lon': -82.53065}},\n",
       "   {'facility': 'Meridien Research',\n",
       "    'city': 'Tampa',\n",
       "    'state': 'Florida',\n",
       "    'zip': '33634',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 27.94752, 'lon': -82.45843}},\n",
       "   {'facility': 'Atlanta Center for Medical Research',\n",
       "    'city': 'Atlanta',\n",
       "    'state': 'Georgia',\n",
       "    'zip': '30331',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.749, 'lon': -84.38798}},\n",
       "   {'facility': 'Columbus Regional Research Institute',\n",
       "    'city': 'Columbus',\n",
       "    'state': 'Georgia',\n",
       "    'zip': '31904',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.46098, 'lon': -84.98771}},\n",
       "   {'facility': 'Georgia Institute for Clinical Research, LLC',\n",
       "    'city': 'Marietta',\n",
       "    'state': 'Georgia',\n",
       "    'zip': '30060',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.9526, 'lon': -84.54993}},\n",
       "   {'facility': 'Advanced Internal Medicine, PC',\n",
       "    'city': 'Stockbridge',\n",
       "    'state': 'Georgia',\n",
       "    'zip': '30281',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.54428, 'lon': -84.23381}},\n",
       "   {'facility': 'Research 1 Clinical Research Network, Inc. (Administrative Office Only)',\n",
       "    'city': 'Stockbridge',\n",
       "    'state': 'Georgia',\n",
       "    'zip': '30281',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.54428, 'lon': -84.23381}},\n",
       "   {'facility': 'Rehabilitation Institute of Chicago',\n",
       "    'city': 'Chicago',\n",
       "    'state': 'Illinois',\n",
       "    'zip': '60611',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "   {'facility': 'Chicago Anesthesia Associates',\n",
       "    'city': 'Chicago',\n",
       "    'state': 'Illinois',\n",
       "    'zip': '60657',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "   {'facility': 'Kansas City Bone & Joint Clinic',\n",
       "    'city': 'Overland Park',\n",
       "    'state': 'Kansas',\n",
       "    'zip': '66211',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.98223, 'lon': -94.67079}},\n",
       "   {'facility': 'Otri-Med Corporation',\n",
       "    'city': 'Edgewood',\n",
       "    'state': 'Kentucky',\n",
       "    'zip': '41017',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 39.01867, 'lon': -84.58189}},\n",
       "   {'facility': 'Central Kentucky Research Associates, Inc.',\n",
       "    'city': 'Lexington',\n",
       "    'state': 'Kentucky',\n",
       "    'zip': '40509',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 37.98869, 'lon': -84.47772}},\n",
       "   {'facility': 'Centex Studies, Inc',\n",
       "    'city': 'Lake Charles',\n",
       "    'state': 'Louisiana',\n",
       "    'zip': '70601',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 30.21309, 'lon': -93.2044}},\n",
       "   {'facility': 'Massachusetts General Hospital',\n",
       "    'city': 'Boston',\n",
       "    'state': 'Massachusetts',\n",
       "    'zip': '02114',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 42.35843, 'lon': -71.05977}},\n",
       "   {'facility': 'Michigan Head Pain and Neurological Institute',\n",
       "    'city': 'Ann Arbor',\n",
       "    'state': 'Michigan',\n",
       "    'zip': '48104',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 42.27756, 'lon': -83.74088}},\n",
       "   {'facility': 'Medex Healthcare Research, Inc.',\n",
       "    'city': 'Saint Louis',\n",
       "    'state': 'Missouri',\n",
       "    'zip': '63117',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.62727, 'lon': -90.19789}},\n",
       "   {'facility': 'Quality Clinical Research, Inc.',\n",
       "    'city': 'Omaha',\n",
       "    'state': 'Nebraska',\n",
       "    'zip': '68114',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.25626, 'lon': -95.94043}},\n",
       "   {'facility': 'Heartland Clinical Research, Inc.',\n",
       "    'city': 'Omaha',\n",
       "    'state': 'Nebraska',\n",
       "    'zip': '68134',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.25626, 'lon': -95.94043}},\n",
       "   {'facility': 'Advanced Biomedical Research of America',\n",
       "    'city': 'Las Vegas',\n",
       "    'state': 'Nevada',\n",
       "    'zip': '89123',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 36.17497, 'lon': -115.13722}},\n",
       "   {'facility': 'University of Rochester, Translational Pain Research',\n",
       "    'city': 'Rochester',\n",
       "    'state': 'New York',\n",
       "    'zip': '14618',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 43.15478, 'lon': -77.61556}},\n",
       "   {'facility': 'PMG Research of Charlotte',\n",
       "    'city': 'Charlotte',\n",
       "    'state': 'North Carolina',\n",
       "    'zip': '28209',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 35.22709, 'lon': -80.84313}},\n",
       "   {'facility': 'PMG Research of Winston-Salem',\n",
       "    'city': 'Winston-Salem',\n",
       "    'state': 'North Carolina',\n",
       "    'zip': '27103',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 36.09986, 'lon': -80.24422}},\n",
       "   {'facility': 'Northern Ohio Neurosciences, LLC',\n",
       "    'city': 'Bellevue',\n",
       "    'state': 'Ohio',\n",
       "    'zip': '44811',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.27366, 'lon': -82.84158}},\n",
       "   {'facility': 'Wells Institute for Health Awareness',\n",
       "    'city': 'Kettering',\n",
       "    'state': 'Ohio',\n",
       "    'zip': '45429',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 39.6895, 'lon': -84.16883}},\n",
       "   {'facility': 'Northwest Ohio Research Center, LLC',\n",
       "    'city': 'Toledo',\n",
       "    'state': 'Ohio',\n",
       "    'zip': '43623',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.66394, 'lon': -83.55521}},\n",
       "   {'facility': 'Robert L Kalb, M.D, Inc',\n",
       "    'city': 'Toledo',\n",
       "    'state': 'Ohio',\n",
       "    'zip': '43623',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 41.66394, 'lon': -83.55521}},\n",
       "   {'facility': 'Cor Clinical Research, Llc',\n",
       "    'city': 'Oklahoma City',\n",
       "    'state': 'Oklahoma',\n",
       "    'zip': '73103',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 35.46756, 'lon': -97.51643}},\n",
       "   {'facility': 'Lynn Health Science Institute',\n",
       "    'city': 'Oklahoma City',\n",
       "    'state': 'Oklahoma',\n",
       "    'zip': '73112',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 35.46756, 'lon': -97.51643}},\n",
       "   {'facility': 'Summit Research Network, Inc.',\n",
       "    'city': 'Portland',\n",
       "    'state': 'Oregon',\n",
       "    'zip': '97210',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 45.52345, 'lon': -122.67621}},\n",
       "   {'facility': 'Allegheny Pain Management, P.C.',\n",
       "    'city': 'Altoona',\n",
       "    'state': 'Pennsylvania',\n",
       "    'zip': '16602',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 40.51868, 'lon': -78.39474}},\n",
       "   {'facility': 'CRI Lifetree',\n",
       "    'city': 'Philadelphia',\n",
       "    'state': 'Pennsylvania',\n",
       "    'zip': '19139',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 39.95233, 'lon': -75.16379}},\n",
       "   {'facility': 'Pharmacorp Clinical Trials, Inc.',\n",
       "    'city': 'Charleston',\n",
       "    'state': 'South Carolina',\n",
       "    'zip': '29412',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.77657, 'lon': -79.93092}},\n",
       "   {'facility': 'TLM Medical Services, LLC',\n",
       "    'city': 'Columbia',\n",
       "    'state': 'South Carolina',\n",
       "    'zip': '29204',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.00071, 'lon': -81.03481}},\n",
       "   {'facility': 'Piedmont Comprehensive Pain Management Group, LLC',\n",
       "    'city': 'Greenville',\n",
       "    'state': 'South Carolina',\n",
       "    'zip': '29601',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.85262, 'lon': -82.39401}},\n",
       "   {'facility': 'Pharmacum Biomedical Research',\n",
       "    'city': 'Greenville',\n",
       "    'state': 'South Carolina',\n",
       "    'zip': '29605',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 34.85262, 'lon': -82.39401}},\n",
       "   {'facility': 'New Phase Research and Development',\n",
       "    'city': 'Knoxville',\n",
       "    'state': 'Tennessee',\n",
       "    'zip': '37919',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 35.96064, 'lon': -83.92074}},\n",
       "   {'facility': 'Dallas Pain Consultants',\n",
       "    'city': 'Dallas',\n",
       "    'state': 'Texas',\n",
       "    'zip': '75203',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.78306, 'lon': -96.80667}},\n",
       "   {'facility': 'FutureSearch Trials of Dallas, L. P.',\n",
       "    'city': 'Dallas',\n",
       "    'state': 'Texas',\n",
       "    'zip': '75231',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.78306, 'lon': -96.80667}},\n",
       "   {'facility': 'Abigail R. Neiman, MD, PA',\n",
       "    'city': 'Houston',\n",
       "    'state': 'Texas',\n",
       "    'zip': '77024',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "   {'facility': 'Agadadash Kuliev, MD, PA',\n",
       "    'city': 'Houston',\n",
       "    'state': 'Texas',\n",
       "    'zip': '77043',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "   {'facility': 'Biopharma Informatic Inc. Research Center',\n",
       "    'city': 'Houston',\n",
       "    'state': 'Texas',\n",
       "    'zip': '77043',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "   {'facility': 'Medstar Clinical Research Associates',\n",
       "    'city': 'Houston',\n",
       "    'state': 'Texas',\n",
       "    'zip': '77083',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "   {'facility': 'ClinRx Research, LLC',\n",
       "    'city': 'Richardson',\n",
       "    'state': 'Texas',\n",
       "    'zip': '75080',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 32.94818, 'lon': -96.72972}},\n",
       "   {'facility': 'DCT - Stone Oak, LLC dba Discovery Clinical Trials',\n",
       "    'city': 'San Antonio',\n",
       "    'state': 'Texas',\n",
       "    'zip': '78258',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.42412, 'lon': -98.49363}},\n",
       "   {'facility': 'Sealy Urgent Care Center and Medical Clinic',\n",
       "    'city': 'Sealy',\n",
       "    'state': 'Texas',\n",
       "    'zip': '77474',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 29.78079, 'lon': -96.15718}},\n",
       "   {'facility': 'Grayline Clinical Drug Trials',\n",
       "    'city': 'Wichita Falls',\n",
       "    'state': 'Texas',\n",
       "    'zip': '76309',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 33.91371, 'lon': -98.49339}},\n",
       "   {'facility': 'Lifetree Clinical Research',\n",
       "    'city': 'Salt Lake City',\n",
       "    'state': 'Utah',\n",
       "    'zip': '84106',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 40.76078, 'lon': -111.89105}},\n",
       "   {'facility': 'J. Lewis Research, Inc./Foothill Family Clinic',\n",
       "    'city': 'Salt Lake City',\n",
       "    'state': 'Utah',\n",
       "    'zip': '84109',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 40.76078, 'lon': -111.89105}},\n",
       "   {'facility': 'J. Lewish Research, Inc./Foothill Family Clinic South',\n",
       "    'city': 'Salt Lake City',\n",
       "    'state': 'Utah',\n",
       "    'zip': '84121',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 40.76078, 'lon': -111.89105}},\n",
       "   {'facility': 'Integrated Neurology Services , PLLC',\n",
       "    'city': 'Arlington',\n",
       "    'state': 'Virginia',\n",
       "    'zip': '22205',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.88101, 'lon': -77.10428}},\n",
       "   {'facility': 'IntegraTrials, LLC',\n",
       "    'city': 'Arlington',\n",
       "    'state': 'Virginia',\n",
       "    'zip': '22205',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 38.88101, 'lon': -77.10428}},\n",
       "   {'facility': 'Washington Center for Pain Management LLC',\n",
       "    'city': 'Bellevue',\n",
       "    'state': 'Washington',\n",
       "    'zip': '98004',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 47.61038, 'lon': -122.20068}},\n",
       "   {'facility': 'Northwest Clinical Research Center',\n",
       "    'city': 'Bellevue',\n",
       "    'state': 'Washington',\n",
       "    'zip': '98007',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 47.61038, 'lon': -122.20068}},\n",
       "   {'facility': 'Washington Center for Pain Management LLC',\n",
       "    'city': 'Edmonds',\n",
       "    'state': 'Washington',\n",
       "    'zip': '98026',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 47.81065, 'lon': -122.37736}},\n",
       "   {'facility': 'Washington Center for Pain Management LLC',\n",
       "    'city': 'Everett',\n",
       "    'state': 'Washington',\n",
       "    'zip': '98201',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 47.97898, 'lon': -122.20208}},\n",
       "   {'facility': 'Washington Center for Pain Management LLC',\n",
       "    'city': 'Renton',\n",
       "    'state': 'Washington',\n",
       "    'zip': '98055',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 47.48288, 'lon': -122.21707}},\n",
       "   {'facility': 'Summit Research Network (Seattle) LLC',\n",
       "    'city': 'Seattle',\n",
       "    'state': 'Washington',\n",
       "    'zip': '98104',\n",
       "    'country': 'United States',\n",
       "    'geoPoint': {'lat': 47.60621, 'lon': -122.33207}},\n",
       "   {'facility': 'MHAT Puls AD',\n",
       "    'city': 'Blagoevgrad',\n",
       "    'zip': '2700',\n",
       "    'country': 'Bulgaria',\n",
       "    'geoPoint': {'lat': 42.01667, 'lon': 23.1}},\n",
       "   {'facility': 'MHAT \"Avis Medika\"',\n",
       "    'city': 'Pleven',\n",
       "    'zip': '5800',\n",
       "    'country': 'Bulgaria',\n",
       "    'geoPoint': {'lat': 43.41667, 'lon': 24.61667}},\n",
       "   {'facility': 'MHAT \"Sv.Pantaleymon\"',\n",
       "    'city': 'Pleven',\n",
       "    'zip': '5800',\n",
       "    'country': 'Bulgaria',\n",
       "    'geoPoint': {'lat': 43.41667, 'lon': 24.61667}},\n",
       "   {'facility': 'DCC Akta Medika Ltd.',\n",
       "    'city': 'Sevlievo',\n",
       "    'zip': '5400',\n",
       "    'country': 'Bulgaria',\n",
       "    'geoPoint': {'lat': 43.02583, 'lon': 25.11361}},\n",
       "   {'facility': 'UMHAT Aleksandrovska',\n",
       "    'city': 'Sofia',\n",
       "    'zip': '1431',\n",
       "    'country': 'Bulgaria',\n",
       "    'geoPoint': {'lat': 42.69751, 'lon': 23.32415}},\n",
       "   {'facility': 'DCC \"Sveta Anna\"EOOD',\n",
       "    'city': 'Sofia',\n",
       "    'zip': '1709',\n",
       "    'country': 'Bulgaria',\n",
       "    'geoPoint': {'lat': 42.69751, 'lon': 23.32415}},\n",
       "   {'facility': 'Aggarwal and Associates Limited',\n",
       "    'city': 'Brampton',\n",
       "    'state': 'Ontario',\n",
       "    'zip': 'L6T 0G1',\n",
       "    'country': 'Canada',\n",
       "    'geoPoint': {'lat': 43.68341, 'lon': -79.76633}},\n",
       "   {'facility': 'NRK Medical Research Clinic (Adminstrative Office Only)',\n",
       "    'city': 'London',\n",
       "    'state': 'Ontario',\n",
       "    'zip': 'N6H 4P2',\n",
       "    'country': 'Canada',\n",
       "    'geoPoint': {'lat': 42.98339, 'lon': -81.23304}},\n",
       "   {'facility': 'NRK Medical Research Clinic',\n",
       "    'city': 'London',\n",
       "    'state': 'Ontario',\n",
       "    'zip': 'N6H 4P2',\n",
       "    'country': 'Canada',\n",
       "    'geoPoint': {'lat': 42.98339, 'lon': -81.23304}},\n",
       "   {'facility': 'London Road Diagnostic Clinic and Medical Centre',\n",
       "    'city': 'Sarnia',\n",
       "    'state': 'Ontario',\n",
       "    'zip': 'N7T 4X3',\n",
       "    'country': 'Canada',\n",
       "    'geoPoint': {'lat': 42.97866, 'lon': -82.40407}},\n",
       "   {'facility': 'General Hospital \"dr. Ivo Pedisic\"',\n",
       "    'city': 'Sisak',\n",
       "    'zip': '44000',\n",
       "    'country': 'Croatia',\n",
       "    'geoPoint': {'lat': 45.46611, 'lon': 16.37833}},\n",
       "   {'facility': 'Glostrup Hospital',\n",
       "    'city': 'Glostrup',\n",
       "    'zip': '2600',\n",
       "    'country': 'Denmark',\n",
       "    'geoPoint': {'lat': 55.6666, 'lon': 12.40377}},\n",
       "   {'facility': 'Klinische Forschung Hannover-Mitte GmbH',\n",
       "    'city': 'Hannover',\n",
       "    'state': 'Niedersachsen',\n",
       "    'zip': '30159',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 52.37052, 'lon': 9.73322}},\n",
       "   {'facility': 'Praxis für Spezielle Schmerztherapie und Palliativmedizin',\n",
       "    'city': 'Böhlen',\n",
       "    'state': 'Sachsen',\n",
       "    'zip': '04564',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 51.20061, 'lon': 12.38622}},\n",
       "   {'facility': 'medamed GmbH Studienambulanz',\n",
       "    'city': 'Leipzig',\n",
       "    'state': 'Sachsen',\n",
       "    'zip': '04109',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 51.33962, 'lon': 12.37129}},\n",
       "   {'facility': 'pro scientia med im MARE Klinikum',\n",
       "    'city': 'Kiel-Kronshagen',\n",
       "    'state': 'Schleswig-holstein',\n",
       "    'zip': '24119',\n",
       "    'country': 'Germany'},\n",
       "   {'facility': 'Klinische Forschung Berlin-Mitte GmbH',\n",
       "    'city': 'Berlin',\n",
       "    'zip': '10117',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 52.52437, 'lon': 13.41053}},\n",
       "   {'facility': 'Synexus Clinical Research GmbH',\n",
       "    'city': 'Berlin',\n",
       "    'zip': '12627',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 52.52437, 'lon': 13.41053}},\n",
       "   {'facility': 'Synexus Clinical Research GmbH',\n",
       "    'city': 'Bochum',\n",
       "    'zip': '44787',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 51.48165, 'lon': 7.21648}},\n",
       "   {'facility': 'Synexus Clinical Research GmbH',\n",
       "    'city': 'Frankfurt',\n",
       "    'zip': '60596',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 50.11552, 'lon': 8.68417}},\n",
       "   {'facility': 'Klinische Forschung Hamburg GmbH',\n",
       "    'city': 'Hamburg',\n",
       "    'zip': '20253',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 53.57532, 'lon': 10.01534}},\n",
       "   {'facility': 'Gemeinschaftspraxis für Schmerz- und Psychotherapie',\n",
       "    'city': 'Hamburg',\n",
       "    'zip': '22767',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 53.57532, 'lon': 10.01534}},\n",
       "   {'facility': 'Synexus Clinical Research GmbH',\n",
       "    'city': 'Leipzig',\n",
       "    'zip': '04103',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 51.33962, 'lon': 12.37129}},\n",
       "   {'facility': 'Klinische Forschung Schwerin GmbH',\n",
       "    'city': 'Schwerin',\n",
       "    'zip': '19055',\n",
       "    'country': 'Germany',\n",
       "    'geoPoint': {'lat': 53.62937, 'lon': 11.41316}},\n",
       "   {'facility': 'Synexus Magyarorszag Kft.',\n",
       "    'city': 'Budapest',\n",
       "    'zip': '1036',\n",
       "    'country': 'Hungary',\n",
       "    'geoPoint': {'lat': 47.49801, 'lon': 19.03991}},\n",
       "   {'facility': 'UNO Medical Trials Kft',\n",
       "    'city': 'Budapest',\n",
       "    'zip': '1135',\n",
       "    'country': 'Hungary',\n",
       "    'geoPoint': {'lat': 47.49801, 'lon': 19.03991}},\n",
       "   {'facility': 'Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz',\n",
       "    'city': 'Miskolc',\n",
       "    'zip': '3526',\n",
       "    'country': 'Hungary',\n",
       "    'geoPoint': {'lat': 48.1, 'lon': 20.78333}},\n",
       "   {'facility': 'Seoul National University Hospital',\n",
       "    'city': 'Seoul',\n",
       "    'zip': '110-744',\n",
       "    'country': 'Korea, Republic of',\n",
       "    'geoPoint': {'lat': 37.566, 'lon': 126.9784}},\n",
       "   {'facility': 'Niepubliczny Zaklad Opieki Zdrowotnej \"Przychodnia Morena\" Sp. z.o.o.',\n",
       "    'city': 'Gdansk',\n",
       "    'zip': '80-286',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 54.35205, 'lon': 18.64637}},\n",
       "   {'facility': '\"SYNEXUS POLSKA\" Sp. z o.o. Oddzial w Gdyni',\n",
       "    'city': 'Gdynia',\n",
       "    'zip': '81-384',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 54.51889, 'lon': 18.53188}},\n",
       "   {'facility': '\"Synexus Polska\" Sp. z o.o. Oddzial W Katowicach',\n",
       "    'city': 'Katowice',\n",
       "    'zip': '40-040',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 50.25841, 'lon': 19.02754}},\n",
       "   {'facility': 'Malopolskie Centrum Medyczne S.C.',\n",
       "    'city': 'Krakow',\n",
       "    'zip': '30-510',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 50.06143, 'lon': 19.93658}},\n",
       "   {'facility': 'NZOZ IGNIS dr n. med. Alicja Lobinska',\n",
       "    'city': 'Swidnik',\n",
       "    'zip': '21-040',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 51.21898, 'lon': 22.69621}},\n",
       "   {'facility': '\"SYNEXUS Polska\" Sp. z o.o. ODDZIAL W WARSZAWIE',\n",
       "    'city': 'Warszawa',\n",
       "    'zip': '01-192',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 52.22977, 'lon': 21.01178}},\n",
       "   {'facility': '\"SYNEXUS POLSKA\" Sp. z o.o. Odzial we Wroclawiu',\n",
       "    'city': 'Wroclaw',\n",
       "    'zip': '50-088',\n",
       "    'country': 'Poland',\n",
       "    'geoPoint': {'lat': 51.1, 'lon': 17.03333}},\n",
       "   {'facility': 'Ponce School of Medicine, CAIMED Center',\n",
       "    'city': 'Ponce',\n",
       "    'zip': '00716',\n",
       "    'country': 'Puerto Rico',\n",
       "    'geoPoint': {'lat': 18.01108, 'lon': -66.61406}},\n",
       "   {'facility': 'Centrul Medical Sana',\n",
       "    'city': 'Bucuresti',\n",
       "    'zip': '011025',\n",
       "    'country': 'Romania',\n",
       "    'geoPoint': {'lat': 44.42802, 'lon': 26.09665}},\n",
       "   {'facility': 'Clubul Sanatatii SRL',\n",
       "    'city': 'Campulung Muscel',\n",
       "    'zip': '115100',\n",
       "    'country': 'Romania',\n",
       "    'geoPoint': {'lat': 45.26667, 'lon': 25.05}},\n",
       "   {'facility': 'Spitalul Clinic de Neuropsihiatrie Craiova',\n",
       "    'city': 'Craiova',\n",
       "    'zip': '200473',\n",
       "    'country': 'Romania',\n",
       "    'geoPoint': {'lat': 44.31667, 'lon': 23.8}},\n",
       "   {'facility': 'Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea,Sectia Neurologie I',\n",
       "    'city': 'Oradea',\n",
       "    'zip': '410154',\n",
       "    'country': 'Romania',\n",
       "    'geoPoint': {'lat': 47.0458, 'lon': 21.91833}},\n",
       "   {'facility': 'Spitalul Clinic Judetean de Urgenta Sibiu,Sectia Neurologie',\n",
       "    'city': 'Sibiu',\n",
       "    'zip': '550166',\n",
       "    'country': 'Romania',\n",
       "    'geoPoint': {'lat': 45.8, 'lon': 24.15}},\n",
       "   {'facility': 'Spitalul Clinic Judetean de Urgenta Targu-Mures , Sectia Neurologie II',\n",
       "    'city': 'Targu Mures',\n",
       "    'zip': '540136',\n",
       "    'country': 'Romania',\n",
       "    'geoPoint': {'lat': 46.54245, 'lon': 24.55747}},\n",
       "   {'facility': 'Welkom Clinical Trial Centre',\n",
       "    'city': 'Welkom',\n",
       "    'state': 'FREE State',\n",
       "    'zip': '9460',\n",
       "    'country': 'South Africa',\n",
       "    'geoPoint': {'lat': -27.97742, 'lon': 26.73506}},\n",
       "   {'facility': 'Synexus SA - Stanza Clinical Research Centre',\n",
       "    'city': 'Pretoria',\n",
       "    'state': 'Gauteng',\n",
       "    'zip': '0122',\n",
       "    'country': 'South Africa',\n",
       "    'geoPoint': {'lat': -25.74486, 'lon': 28.18783}},\n",
       "   {'facility': 'Synexus SA - Watermeyer Clinical Research Centre',\n",
       "    'city': 'Pretoria',\n",
       "    'state': 'Gauteng',\n",
       "    'zip': '0184',\n",
       "    'country': 'South Africa',\n",
       "    'geoPoint': {'lat': -25.74486, 'lon': 28.18783}},\n",
       "   {'facility': 'Synexus SA - Roodepoort Medicross Clinical Research Centre',\n",
       "    'city': 'Roodeport',\n",
       "    'state': 'Gauteng',\n",
       "    'zip': '1724',\n",
       "    'country': 'South Africa'},\n",
       "   {'facility': 'Ladulaas Kliniken',\n",
       "    'city': 'Boras',\n",
       "    'zip': '506 30',\n",
       "    'country': 'Sweden',\n",
       "    'geoPoint': {'lat': 57.72101, 'lon': 12.9401}},\n",
       "   {'facility': 'CTC, Gothia Forum, Sahlgrenska Universitetssjukhus',\n",
       "    'city': 'Göteborg',\n",
       "    'zip': '413 45',\n",
       "    'country': 'Sweden',\n",
       "    'geoPoint': {'lat': 57.70716, 'lon': 11.96679}},\n",
       "   {'facility': 'Probare',\n",
       "    'city': 'Lund',\n",
       "    'zip': '222 22',\n",
       "    'country': 'Sweden',\n",
       "    'geoPoint': {'lat': 55.70584, 'lon': 13.19321}},\n",
       "   {'facility': 'Pharmasite',\n",
       "    'city': 'Malmö',\n",
       "    'zip': '211 52',\n",
       "    'country': 'Sweden',\n",
       "    'geoPoint': {'lat': 55.60587, 'lon': 13.00073}},\n",
       "   {'facility': 'Bragee Medect AB',\n",
       "    'city': 'Stockholm',\n",
       "    'zip': '115 26',\n",
       "    'country': 'Sweden',\n",
       "    'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}]},\n",
       " 'referencesModule': {'references': [{'pmid': '30242745',\n",
       "    'type': 'DERIVED',\n",
       "    'citation': 'Markman J, Resnick M, Greenberg S, Katz N, Yang R, Scavone J, Whalen E, Gregorian G, Parsons B, Knapp L. Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. J Neurol. 2018 Dec;265(12):2815-2824. doi: 10.1007/s00415-018-9063-9. Epub 2018 Sep 21.'}],\n",
       "  'seeAlsoLinks': [{'label': 'To obtain contact information for a study center near you, click here.',\n",
       "    'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081279&StudyName=Placebo-controlled%20safety%20and%20efficacy%20study%20of%20pregabalin%20in%20subjects%20with%20post-traumatic%20peripheral%20neuropathic%20pain'}]}}"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "studies[0][\"protocolSection\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'participantFlowModule': {'preAssignmentDetails': 'Participants had clinic visits at screening, randomization, and during the treatment period, and a phone contact for follow-up after the last taper dose. All the eligible participants were randomly assigned (1:1) to 15 weeks of treatment with Pregabalin or Placebo.',\n",
       "  'recruitmentDetails': 'A total of 187 centers participated in the study in 14 countries.\\n\\nDuring screening, with the exception of daily pain score data that was collected to determine participants eligibility, no participants were treated with active drug and no efficacy data were collected. Only safety and no efficacy data was collected during the taper period.',\n",
       "  'groups': [{'id': 'FG000',\n",
       "    'title': 'Pregabalin',\n",
       "    'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "   {'id': 'FG001',\n",
       "    'title': 'Placebo',\n",
       "    'description': 'Participants randomized to receive placebo'}],\n",
       "  'periods': [{'title': 'Overall Study',\n",
       "    'milestones': [{'type': 'STARTED',\n",
       "      'achievements': [{'groupId': 'FG000', 'numSubjects': '275'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '267'}]},\n",
       "     {'type': 'TREATED',\n",
       "      'achievements': [{'groupId': 'FG000', 'numSubjects': '274'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '265'}]},\n",
       "     {'type': 'COMPLETED',\n",
       "      'achievements': [{'groupId': 'FG000', 'numSubjects': '233'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '211'}]},\n",
       "     {'type': 'NOT COMPLETED',\n",
       "      'achievements': [{'groupId': 'FG000', 'numSubjects': '42'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '56'}]}],\n",
       "    'dropWithdraws': [{'type': 'Adverse events not related to study drug',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '1'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '6'}]},\n",
       "     {'type': 'Adverse events related to study drug',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '12'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '10'}]},\n",
       "     {'type': 'Protocol Violation',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '5'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '3'}]},\n",
       "     {'type': 'No longer willing to participate',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '8'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '14'}]},\n",
       "     {'type': 'Lost to Follow-up',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '6'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '9'}]},\n",
       "     {'type': 'Insufficient clinical response',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '6'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '6'}]},\n",
       "     {'type': 'Death',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '0'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '1'}]},\n",
       "     {'type': 'Randomized but not treated',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '1'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '2'}]},\n",
       "     {'type': 'Reasons other than those mentioned above',\n",
       "      'reasons': [{'groupId': 'FG000', 'numSubjects': '3'},\n",
       "       {'groupId': 'FG001', 'numSubjects': '5'}]}]}]},\n",
       " 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000',\n",
       "    'title': 'Pregabalin',\n",
       "    'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "   {'id': 'BG001',\n",
       "    'title': 'Placebo',\n",
       "    'description': 'Participants randomized to receive placebo'},\n",
       "   {'id': 'BG002',\n",
       "    'title': 'Total',\n",
       "    'description': 'Total of all reporting groups'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'BG000', 'value': '274'},\n",
       "     {'groupId': 'BG001', 'value': '265'},\n",
       "     {'groupId': 'BG002', 'value': '539'}]}],\n",
       "  'measures': [{'title': 'Age, Continuous',\n",
       "    'paramType': 'MEAN',\n",
       "    'dispersionType': 'STANDARD_DEVIATION',\n",
       "    'unitOfMeasure': 'Years',\n",
       "    'classes': [{'categories': [{'measurements': [{'groupId': 'BG000',\n",
       "          'value': '52.8',\n",
       "          'spread': '12.9'},\n",
       "         {'groupId': 'BG001', 'value': '53.4', 'spread': '12.7'},\n",
       "         {'groupId': 'BG002', 'value': '53.1', 'spread': '12.8'}]}]}]},\n",
       "   {'title': 'Age, Customized',\n",
       "    'paramType': 'NUMBER',\n",
       "    'unitOfMeasure': 'Participants',\n",
       "    'classes': [{'title': '18 - 44 years',\n",
       "      'categories': [{'measurements': [{'groupId': 'BG000', 'value': '59'},\n",
       "         {'groupId': 'BG001', 'value': '61'},\n",
       "         {'groupId': 'BG002', 'value': '120'}]}]},\n",
       "     {'title': '45 - 64 years',\n",
       "      'categories': [{'measurements': [{'groupId': 'BG000', 'value': '163'},\n",
       "         {'groupId': 'BG001', 'value': '154'},\n",
       "         {'groupId': 'BG002', 'value': '317'}]}]},\n",
       "     {'title': '>=65 years',\n",
       "      'categories': [{'measurements': [{'groupId': 'BG000', 'value': '52'},\n",
       "         {'groupId': 'BG001', 'value': '50'},\n",
       "         {'groupId': 'BG002', 'value': '102'}]}]}]},\n",
       "   {'title': 'Sex: Female, Male',\n",
       "    'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "    'unitOfMeasure': 'Participants',\n",
       "    'classes': [{'categories': [{'title': 'Female',\n",
       "        'measurements': [{'groupId': 'BG000', 'value': '132'},\n",
       "         {'groupId': 'BG001', 'value': '134'},\n",
       "         {'groupId': 'BG002', 'value': '266'}]},\n",
       "       {'title': 'Male',\n",
       "        'measurements': [{'groupId': 'BG000', 'value': '142'},\n",
       "         {'groupId': 'BG001', 'value': '131'},\n",
       "         {'groupId': 'BG002', 'value': '273'}]}]}]}]},\n",
       " 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY',\n",
       "    'title': 'Baseline Mean Pain Score',\n",
       "    'description': 'This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 (\"no pain\") to 10 (\"worst possible pain\"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.',\n",
       "    'populationDescription': 'Intent to Treat (ITT) population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'MEAN',\n",
       "    'dispersionType': 'Standard Deviation',\n",
       "    'unitOfMeasure': 'units on a scale',\n",
       "    'timeFrame': 'Baseline',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '6.41',\n",
       "          'spread': '1.30'},\n",
       "         {'groupId': 'OG001', 'value': '6.54', 'spread': '1.30'}]}]}]},\n",
       "   {'type': 'PRIMARY',\n",
       "    'title': 'Change From Baseline to Week 15 in Weekly Mean Pain Score',\n",
       "    'description': 'This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 (\"no pain\") to 10 (\"worst possible pain\"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10.',\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'LEAST_SQUARES_MEAN',\n",
       "    'dispersionType': 'Standard Error',\n",
       "    'unitOfMeasure': 'units on a scale',\n",
       "    'timeFrame': 'up to Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.12',\n",
       "          'spread': '0.15'},\n",
       "         {'groupId': 'OG001', 'value': '-1.90', 'spread': '0.16'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1823',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Mixed Model Repeated Measures = MMRM',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '-0.22',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.54',\n",
       "      'ciUpperLimit': '0.10',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.16',\n",
       "      'estimateComment': 'MMRM analysis includes fixed categorical effects of treatment, country, trauma type, visit week, treatment-by-visit interaction, and fixed continuous effect of baseline value. Missing mean pain scores imputed by multiple imputation method'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Patient Global Impression of Change (PGIC) at Week 15',\n",
       "    'description': \"A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale.\",\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'NUMBER',\n",
       "    'unitOfMeasure': 'Participants',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '258'},\n",
       "       {'groupId': 'OG001', 'value': '246'}]}],\n",
       "    'classes': [{'title': 'Very much improved',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '52'},\n",
       "         {'groupId': 'OG001', 'value': '41'}]}]},\n",
       "     {'title': 'Much improved',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '105'},\n",
       "         {'groupId': 'OG001', 'value': '79'}]}]},\n",
       "     {'title': 'Minimally improved',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '61'},\n",
       "         {'groupId': 'OG001', 'value': '62'}]}]},\n",
       "     {'title': 'No change',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '34'},\n",
       "         {'groupId': 'OG001', 'value': '51'}]}]},\n",
       "     {'title': 'Minimally worse',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5'},\n",
       "         {'groupId': 'OG001', 'value': '9'}]}]},\n",
       "     {'title': 'Much worse',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'},\n",
       "         {'groupId': 'OG001', 'value': '4'}]}]},\n",
       "     {'title': 'Very much worse',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'},\n",
       "         {'groupId': 'OG001', 'value': '0'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0012',\n",
       "      'pValueComment': 'The p-value is derived from CMH test, stratified for pooled center and trauma type and excludes missing values.',\n",
       "      'statisticalMethod': 'Cochran-Mantel-Haenszel'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS)',\n",
       "    'description': 'This is an 11-point NRS ranging from 0 (\"pain does not interfere with sleep\") to 10 (\"pain completely interferes with sleep\" \\\\[unable to sleep due to pain\\\\]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context.\\n\\nNote: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week \\'n\\' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7\\\\*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings.\\n\\n\"Overall\" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks.',\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'MEAN',\n",
       "    'dispersionType': 'Standard Deviation',\n",
       "    'unitOfMeasure': 'units on a scale',\n",
       "    'timeFrame': 'up to Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Baseline (raw scores) (N = 274, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '4.97',\n",
       "          'spread': '2.30'},\n",
       "         {'groupId': 'OG001', 'value': '4.99', 'spread': '2.27'}]}]},\n",
       "     {'title': 'Week 1 (N = 260, 258)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-0.66',\n",
       "          'spread': '1.10'},\n",
       "         {'groupId': 'OG001', 'value': '-0.28', 'spread': '0.91'}]}]},\n",
       "     {'title': 'Week 2 (N = 254, 244)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.15',\n",
       "          'spread': '1.51'},\n",
       "         {'groupId': 'OG001', 'value': '-0.81', 'spread': '1.27'}]}]},\n",
       "     {'title': 'Week 3 (N = 252, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.55',\n",
       "          'spread': '1.73'},\n",
       "         {'groupId': 'OG001', 'value': '-1.14', 'spread': '1.45'}]}]},\n",
       "     {'title': 'Week 4 (N = 245, 229)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.73',\n",
       "          'spread': '1.80'},\n",
       "         {'groupId': 'OG001', 'value': '-1.30', 'spread': '1.63'}]}]},\n",
       "     {'title': 'Week 5 (N = 241, 226)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.87',\n",
       "          'spread': '1.87'},\n",
       "         {'groupId': 'OG001', 'value': '-1.40', 'spread': '1.68'}]}]},\n",
       "     {'title': 'Week 6 (N = 244, 227)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.94',\n",
       "          'spread': '1.95'},\n",
       "         {'groupId': 'OG001', 'value': '-1.46', 'spread': '1.79'}]}]},\n",
       "     {'title': 'Week 7 (N = 240, 216)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.01',\n",
       "          'spread': '1.99'},\n",
       "         {'groupId': 'OG001', 'value': '-1.50', 'spread': '1.78'}]}]},\n",
       "     {'title': 'Week 8 (N = 236, 212)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.05',\n",
       "          'spread': '2.00'},\n",
       "         {'groupId': 'OG001', 'value': '-1.52', 'spread': '1.76'}]}]},\n",
       "     {'title': 'Week 9 (N = 232, 214)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.09',\n",
       "          'spread': '1.99'},\n",
       "         {'groupId': 'OG001', 'value': '-1.55', 'spread': '1.86'}]}]},\n",
       "     {'title': 'Week 10 (N = 229, 212)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.04',\n",
       "          'spread': '2.11'},\n",
       "         {'groupId': 'OG001', 'value': '-1.55', 'spread': '1.83'}]}]},\n",
       "     {'title': 'Week 11 (N = 230, 211)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.09',\n",
       "          'spread': '2.05'},\n",
       "         {'groupId': 'OG001', 'value': '-1.64', 'spread': '1.79'}]}]},\n",
       "     {'title': 'Week 12 (N = 227, 209)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.17',\n",
       "          'spread': '2.06'},\n",
       "         {'groupId': 'OG001', 'value': '-1.68', 'spread': '1.89'}]}]},\n",
       "     {'title': 'Week 13 (N = 225, 204)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.19',\n",
       "          'spread': '2.06'},\n",
       "         {'groupId': 'OG001', 'value': '-1.70', 'spread': '1.90'}]}]},\n",
       "     {'title': 'Week 14 (N = 222, 208)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.19',\n",
       "          'spread': '2.16'},\n",
       "         {'groupId': 'OG001', 'value': '-1.79', 'spread': '1.89'}]}]},\n",
       "     {'title': 'Week 15 (N = 196, 186)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.13',\n",
       "          'spread': '2.17'},\n",
       "         {'groupId': 'OG001', 'value': '-1.83', 'spread': '1.87'}]}]},\n",
       "     {'title': 'Overall (N = 269, 262)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.83',\n",
       "          'spread': '1.93'},\n",
       "         {'groupId': 'OG001', 'value': '-1.37', 'spread': '1.71'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 1',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0119',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.35',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.62',\n",
       "      'ciUpperLimit': '-0.08',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 2',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0135',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.34',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.62',\n",
       "      'ciUpperLimit': '-0.07',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 3',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0028',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.42',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.69',\n",
       "      'ciUpperLimit': '-0.14',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 4',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0016',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.44',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.72',\n",
       "      'ciUpperLimit': '-0.17',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 5',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0007',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.48',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.75',\n",
       "      'ciUpperLimit': '-0.20',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 6',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0006',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.48',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.76',\n",
       "      'ciUpperLimit': '-0.21',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 7',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0008',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.48',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.75',\n",
       "      'ciUpperLimit': '-0.20',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 8',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0003',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.52',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.79',\n",
       "      'ciUpperLimit': '-0.24',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 9',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0001',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.54',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.82',\n",
       "      'ciUpperLimit': '-0.26',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 10',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0005',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.49',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.77',\n",
       "      'ciUpperLimit': '-0.22',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 11',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0007',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.48',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.76',\n",
       "      'ciUpperLimit': '-0.20',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 12',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0001',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.54',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.82',\n",
       "      'ciUpperLimit': '-0.27',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 13',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '<0.0001',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.56',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.84',\n",
       "      'ciUpperLimit': '-0.28',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 14',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0005',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.50',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.78',\n",
       "      'ciUpperLimit': '-0.22',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.14'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Week 15',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0031',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.43',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.71',\n",
       "      'ciUpperLimit': '-0.14',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.15'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Overall',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0001',\n",
       "      'statisticalMethod': 'Mixed Model Repeated Measures Analysis',\n",
       "      'statisticalComment': 'Analyzed for treatment, center, trauma type, week \\\\& treatment-by-week interaction and fixed continuous effect of baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.47',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.71',\n",
       "      'ciUpperLimit': '-0.23',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.12'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf])',\n",
       "    'description': 'A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome.',\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'LEAST_SQUARES_MEAN',\n",
       "    'dispersionType': 'Standard Error',\n",
       "    'unitOfMeasure': 'units on a scale',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '258'},\n",
       "       {'groupId': 'OG001', 'value': '246'}]}],\n",
       "    'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.40',\n",
       "          'spread': '0.13',\n",
       "          'lowerLimit': '-8.3',\n",
       "          'upperLimit': '2.5'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-1.95',\n",
       "          'spread': '0.13',\n",
       "          'lowerLimit': '-6.5',\n",
       "          'upperLimit': '2.5'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0050',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This secondary endpoint has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '-0.46',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.77',\n",
       "      'ciUpperLimit': '-0.14',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.16'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Change From Baseline in Pain Interference Index (BPI-sf)',\n",
       "    'description': 'BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation.\\n\\nIt consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes).\\n\\nThe BPI-sf pain interference index was calculated as average of the seven individual pain interference scores.',\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'LEAST_SQUARES_MEAN',\n",
       "    'dispersionType': 'Standard Error',\n",
       "    'unitOfMeasure': 'units on a scale',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.72',\n",
       "          'spread': '0.13',\n",
       "          'lowerLimit': '-1.97',\n",
       "          'upperLimit': '-1.46'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-1.33',\n",
       "          'spread': '0.13',\n",
       "          'lowerLimit': '-1.59',\n",
       "          'upperLimit': '-1.07'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0168',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This secondary endpoint has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'Mean Difference (Final Values)',\n",
       "      'paramValue': '-0.38',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.70',\n",
       "      'ciUpperLimit': '-0.07',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.16'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores',\n",
       "    'description': \"A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale.\",\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'LEAST_SQUARES_MEAN',\n",
       "    'dispersionType': 'Standard Error',\n",
       "    'unitOfMeasure': 'Units on a scale',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Mobility',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-0.10',\n",
       "          'spread': '0.03',\n",
       "          'lowerLimit': '-0.16',\n",
       "          'upperLimit': '-0.05'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-0.09',\n",
       "          'spread': '0.03',\n",
       "          'lowerLimit': '-0.15',\n",
       "          'upperLimit': '-0.03'}]}]},\n",
       "     {'title': 'Self-care',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-0.08',\n",
       "          'spread': '0.02',\n",
       "          'lowerLimit': '-0.12',\n",
       "          'upperLimit': '0.04'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-0.06',\n",
       "          'spread': '0.02',\n",
       "          'lowerLimit': '-0.11',\n",
       "          'upperLimit': '-0.02'}]}]},\n",
       "     {'title': 'Usual activities',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-0.12',\n",
       "          'spread': '0.03',\n",
       "          'lowerLimit': '-0.19',\n",
       "          'upperLimit': '-0.05'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-0.13',\n",
       "          'spread': '0.04',\n",
       "          'lowerLimit': '-0.20',\n",
       "          'upperLimit': '-0.06'}]}]},\n",
       "     {'title': 'Pain/Discomfort',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-0.35',\n",
       "          'spread': '0.03',\n",
       "          'lowerLimit': '-0.42',\n",
       "          'upperLimit': '-0.28'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-0.29',\n",
       "          'spread': '0.04',\n",
       "          'lowerLimit': '-0.36',\n",
       "          'upperLimit': '-0.22'}]}]},\n",
       "     {'title': 'Anxiety/Depression',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '0.01',\n",
       "          'spread': '0.03',\n",
       "          'lowerLimit': '-0.05',\n",
       "          'upperLimit': '0.07'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-0.02',\n",
       "          'spread': '0.03',\n",
       "          'lowerLimit': '-0.08',\n",
       "          'upperLimit': '0.04'}]}]},\n",
       "     {'title': 'Dolan 1997 Index Score',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '0.12',\n",
       "          'spread': '0.01'},\n",
       "         {'groupId': 'OG001', 'value': '0.11', 'spread': '0.01'}]}]},\n",
       "     {'title': 'Dolan 2001 Index Score',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-0.13',\n",
       "          'spread': '0.02'},\n",
       "         {'groupId': 'OG001', 'value': '-0.12', 'spread': '0.02'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for mobility',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.6841',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '-0.01',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.09',\n",
       "      'ciUpperLimit': '0.06',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.037'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for self-care',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.6564',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '-0.01',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.07',\n",
       "      'ciUpperLimit': '0.04',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.029'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for usual activities',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.8590',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '0.01',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.08',\n",
       "      'ciUpperLimit': '0.09',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.043'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for pain/discomfort',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1628',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '-0.06',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.14',\n",
       "      'ciUpperLimit': '0.02',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.043'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for anxiety/depression',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.4654',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'leaset squares mean difference',\n",
       "      'paramValue': '0.03',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.05',\n",
       "      'ciUpperLimit': '0.10',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.037'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for Dolan 1997 Index score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.5000',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least squares mean difference',\n",
       "      'paramValue': '0.01',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.02',\n",
       "      'ciUpperLimit': '0.04',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.017'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'This statistical analysis is for Dolan 2001 Index Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.5493',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'leaset squares mean difference',\n",
       "      'paramValue': '-0.02',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.07',\n",
       "      'ciUpperLimit': '0.04',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.026'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.',\n",
       "    'description': 'MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores.\\n\\nSleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement.\\n\\nSleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement.\\n\\nQuantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement.\\n\\nOptimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.',\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug.',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'MEDIAN',\n",
       "    'dispersionType': 'Full Range',\n",
       "    'unitOfMeasure': 'Units on a scale',\n",
       "    'timeFrame': 'Baseline',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Sleep Disturbance Score (N = 274, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '42.50',\n",
       "          'spread': '25.791',\n",
       "          'lowerLimit': '0',\n",
       "          'upperLimit': '100'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '43.75',\n",
       "          'spread': '25.080',\n",
       "          'lowerLimit': '0',\n",
       "          'upperLimit': '100'}]}]},\n",
       "     {'title': 'Sleep Adequancy Score (N = 274, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '40.0',\n",
       "          'spread': '28.153',\n",
       "          'lowerLimit': '0',\n",
       "          'upperLimit': '100'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '40.0',\n",
       "          'spread': '28.582',\n",
       "          'lowerLimit': '0',\n",
       "          'upperLimit': '100'}]}]},\n",
       "     {'title': 'Snoring Score (N = 272, 263)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '20.0',\n",
       "          'spread': '33.482',\n",
       "          'lowerLimit': '0',\n",
       "          'upperLimit': '100'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '20.0',\n",
       "          'spread': '34.084',\n",
       "          'lowerLimit': '0',\n",
       "          'upperLimit': '100'}]}]},\n",
       "     {'title': 'Awaken Short of Breath Score (N = 274, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '0.0',\n",
       "          'spread': '25.647',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '100'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '0.0',\n",
       "          'spread': '21.541',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '100'}]}]},\n",
       "     {'title': 'Quantity of Sleep Score (hours) (N = 273, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '6.0',\n",
       "          'spread': '1.360',\n",
       "          'lowerLimit': '2.0',\n",
       "          'upperLimit': '10.0'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '6.0',\n",
       "          'spread': '1.411',\n",
       "          'lowerLimit': '2.0',\n",
       "          'upperLimit': '10.0'}]}]},\n",
       "     {'title': 'Somnolence Score (N = 274, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '26.67',\n",
       "          'spread': '21.618',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '100'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '26.67',\n",
       "          'spread': '19.884',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '100'}]}]},\n",
       "     {'title': 'Sleep Problem Index (9) Score (N = 274, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '40.56',\n",
       "          'spread': '20.282',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '88.3'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '41.11',\n",
       "          'spread': '19.720',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '88.9'}]}]},\n",
       "     {'title': 'Optimal Sleep Score (N = 273, 265)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '0.0',\n",
       "          'spread': '0.476',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '1.0'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '0.0',\n",
       "          'spread': '0.487',\n",
       "          'lowerLimit': '0.0',\n",
       "          'upperLimit': '1.0'}]}]}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score.',\n",
       "    'description': 'MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores.\\n\\nSleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement.\\n\\nSleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement.\\n\\nQuantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement.\\n\\nOptimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours.',\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug.',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'LEAST_SQUARES_MEAN',\n",
       "    'dispersionType': '95% Confidence Interval',\n",
       "    'unitOfMeasure': 'Units on a scale',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Sleep Disturbance Score (N = 257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-14.71',\n",
       "          'lowerLimit': '-17.57',\n",
       "          'upperLimit': '-11.85'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-11.24',\n",
       "          'lowerLimit': '-14.16',\n",
       "          'upperLimit': '-8.33'}]}]},\n",
       "     {'title': 'Sleep Adequancy Score (N=257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '10.13',\n",
       "          'lowerLimit': '6.49',\n",
       "          'upperLimit': '13.76'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '8.16',\n",
       "          'lowerLimit': '4.43',\n",
       "          'upperLimit': '11.89'}]}]},\n",
       "     {'title': 'Snoring Score (N = 257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-2.22',\n",
       "          'lowerLimit': '-5.46',\n",
       "          'upperLimit': '1.03'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-3.27',\n",
       "          'lowerLimit': '-6.59',\n",
       "          'upperLimit': '0.04'}]}]},\n",
       "     {'title': 'Awaken Short of Breath Score (N = 257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-3.61',\n",
       "          'lowerLimit': '-6.30',\n",
       "          'upperLimit': '-0.92'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-3.03',\n",
       "          'lowerLimit': '-5.78',\n",
       "          'upperLimit': '-0.27'}]}]},\n",
       "     {'title': 'Quantity of Sleep Score (hours) (N = 257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '0.42',\n",
       "          'lowerLimit': '0.19',\n",
       "          'upperLimit': '0.66'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '0.26',\n",
       "          'lowerLimit': '0.03',\n",
       "          'upperLimit': '0.50'}]}]},\n",
       "     {'title': 'Somnolence Score (N = 257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-1.61',\n",
       "          'lowerLimit': '-3.99',\n",
       "          'upperLimit': '0.77'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-3.74',\n",
       "          'lowerLimit': '-6.17',\n",
       "          'upperLimit': '-1.31'}]}]},\n",
       "     {'title': 'Sleep Problem Index (9) Score (N = 257, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '-9.86',\n",
       "          'lowerLimit': '-12.17',\n",
       "          'upperLimit': '-7.56'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '-8.19',\n",
       "          'lowerLimit': '-10.55',\n",
       "          'upperLimit': '-5.83'}]}]},\n",
       "     {'title': 'Optimal Sleep Score (N = 256, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "          'value': '0.11',\n",
       "          'lowerLimit': '0.05',\n",
       "          'upperLimit': '0.18'},\n",
       "         {'groupId': 'OG001',\n",
       "          'value': '0.04',\n",
       "          'lowerLimit': '-0.03',\n",
       "          'upperLimit': '0.10'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Sleep Disturbance Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0545',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '3.5',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.07',\n",
       "      'ciUpperLimit': '7.00',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '1.80'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Sleep Adequancy Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.3913',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-2.0',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-6.47',\n",
       "      'ciUpperLimit': '2.54',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '2.29'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Snoring Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.6059',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-1.1',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-5.06',\n",
       "      'ciUpperLimit': '2.96',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '2.04'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Awaken Short of Breath Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.7317',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '0.6',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-2.76',\n",
       "      'ciUpperLimit': '3.93',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '1.70'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Quantity of Sleep Score (hours)',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.2663',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-0.2',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.45',\n",
       "      'ciUpperLimit': '0.12',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.15'},\n",
       "     {'groupIds': ['OG000'],\n",
       "      'groupDescription': 'Statistical analysis for Somnolence Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1562',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '-2.1',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-5.08',\n",
       "      'ciUpperLimit': '0.82',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '1.50'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Sleep Problem Index (9) Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.2490',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'least square mean difference',\n",
       "      'paramValue': '1.7',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-1.18',\n",
       "      'ciUpperLimit': '4.53',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '1.45'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis for Optimal Sleep Score',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0609',\n",
       "      'statisticalMethod': 'ANCOVA',\n",
       "      'statisticalComment': 'This sub-score has been analyzed using ANCOVA with model terms of treatment, center, trauma type and baseline value on the ITT population.',\n",
       "      'paramType': 'leaet squares mean difference',\n",
       "      'paramValue': '-0.1',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '-0.15',\n",
       "      'ciUpperLimit': '0.00',\n",
       "      'dispersionType': 'STANDARD_ERROR_OF_MEAN',\n",
       "      'dispersionValue': '0.04'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Percentage of Participants in MOS-SS With Optimal Sleep Status.',\n",
       "    'description': 'MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable.',\n",
       "    'populationDescription': 'ITT population: all randomized subjects who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'NUMBER',\n",
       "    'unitOfMeasure': 'Percentage of participants',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Any Improvements',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21.2'},\n",
       "         {'groupId': 'OG001', 'value': '18.5'}]}]},\n",
       "     {'title': 'No Change',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '66.1'},\n",
       "         {'groupId': 'OG001', 'value': '60.8'}]}]},\n",
       "     {'title': 'Any Worsening',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.2'},\n",
       "         {'groupId': 'OG001', 'value': '13.2'}]}]},\n",
       "     {'title': 'Not applicable',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.6'},\n",
       "         {'groupId': 'OG001', 'value': '7.5'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.7165',\n",
       "      'pValueComment': 'p-values based on CMH test stratified by pooled center and trauma type, patients with unknown status at baseline or endpoint will not be included in the calculation of p-values.',\n",
       "      'statisticalMethod': 'Cochran-Mantel-Haenszel'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%.',\n",
       "    'description': \"Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\\\\*(n-1) to Day 1+7\\\\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.\",\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'NUMBER',\n",
       "    'unitOfMeasure': 'Percentage of participants',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Week 1 (N = 260, 258)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11.92'},\n",
       "         {'groupId': 'OG001', 'value': '5.04'}]}]},\n",
       "     {'title': 'Week 2 (N = 254, 244)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '27.17'},\n",
       "         {'groupId': 'OG001', 'value': '20.08'}]}]},\n",
       "     {'title': 'Week 3 (N = 252, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '38.89'},\n",
       "         {'groupId': 'OG001', 'value': '30.20'}]}]},\n",
       "     {'title': 'Week 4 (N = 246, 229)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '41.87'},\n",
       "         {'groupId': 'OG001', 'value': '34.50'}]}]},\n",
       "     {'title': 'Week 5 (N = 241, 226)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '45.64'},\n",
       "         {'groupId': 'OG001', 'value': '38.05'}]}]},\n",
       "     {'title': 'Week 6 (N = 244, 227)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '48.77'},\n",
       "         {'groupId': 'OG001', 'value': '41.41'}]}]},\n",
       "     {'title': 'Week 7 (N = 240, 216)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '49.58'},\n",
       "         {'groupId': 'OG001', 'value': '43.06'}]}]},\n",
       "     {'title': 'Week 8 (N = 236, 213)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '50.42'},\n",
       "         {'groupId': 'OG001', 'value': '46.48'}]}]},\n",
       "     {'title': 'Week 9 (N = 232, 214)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '50.86'},\n",
       "         {'groupId': 'OG001', 'value': '47.66'}]}]},\n",
       "     {'title': 'Week 10 (N = 229, 212)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '52.84'},\n",
       "         {'groupId': 'OG001', 'value': '47.17'}]}]},\n",
       "     {'title': 'Week 11 (N = 231, 211)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '52.38'},\n",
       "         {'groupId': 'OG001', 'value': '51.18'}]}]},\n",
       "     {'title': 'Week 12 (N = 227, 209)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '54.63'},\n",
       "         {'groupId': 'OG001', 'value': '52.63'}]}]},\n",
       "     {'title': 'Week 13 (N = 226, 204)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '57.08'},\n",
       "         {'groupId': 'OG001', 'value': '54.41'}]}]},\n",
       "     {'title': 'Week 14 (N = 223, 208)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '57.40'},\n",
       "         {'groupId': 'OG001', 'value': '54.33'}]}]},\n",
       "     {'title': 'Week 15 (N = 196, 187)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '57.65'},\n",
       "         {'groupId': 'OG001', 'value': '58.29'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 1',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0028',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '3.20',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.50',\n",
       "      'ciUpperLimit': '6.86'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 2',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0360',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.66',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.03',\n",
       "      'ciUpperLimit': '2.68'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 3',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0235',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.62',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.07',\n",
       "      'ciUpperLimit': '2.45'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 4',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0619',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.48',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.98',\n",
       "      'ciUpperLimit': '2.24'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 5',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0677',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.46',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.97',\n",
       "      'ciUpperLimit': '2.20'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 6',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0707',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.45',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.97',\n",
       "      'ciUpperLimit': '2.16'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 7',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1313',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.37',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.91',\n",
       "      'ciUpperLimit': '2.06'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 8',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.3072',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.24',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.82',\n",
       "      'ciUpperLimit': '1.86'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 9',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.3947',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.19',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.79',\n",
       "      'ciUpperLimit': '1.80'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 10',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1462',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.36',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.90',\n",
       "      'ciUpperLimit': '2.05'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 11',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.6854',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.09',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.72',\n",
       "      'ciUpperLimit': '1.64'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 12',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.5025',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.15',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.76',\n",
       "      'ciUpperLimit': '1.74'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 13',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.4908',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.16',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.76',\n",
       "      'ciUpperLimit': '1.76'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 14',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.4245',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.19',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.78',\n",
       "      'ciUpperLimit': '1.80'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 15',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.8464',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '0.96',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.61',\n",
       "      'ciUpperLimit': '1.49'}]},\n",
       "   {'type': 'SECONDARY',\n",
       "    'title': 'Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50%',\n",
       "    'description': \"Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7\\\\*(n-1) to Day 1+7\\\\*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain.\",\n",
       "    'populationDescription': 'ITT population: all randomized participants who took at least one dose of study drug',\n",
       "    'reportingStatus': 'POSTED',\n",
       "    'paramType': 'NUMBER',\n",
       "    'unitOfMeasure': 'Percentage of participants',\n",
       "    'timeFrame': 'Week 15',\n",
       "    'groups': [{'id': 'OG000',\n",
       "      'title': 'Pregabalin',\n",
       "      'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.'},\n",
       "     {'id': 'OG001',\n",
       "      'title': 'Placebo',\n",
       "      'description': 'Participants randomized to receive placebo'}],\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '274'},\n",
       "       {'groupId': 'OG001', 'value': '265'}]}],\n",
       "    'classes': [{'title': 'Week 1 (N = 260, 258)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.62'},\n",
       "         {'groupId': 'OG001', 'value': '2.33'}]}]},\n",
       "     {'title': 'Week 2 (N = 254, 244)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11.42'},\n",
       "         {'groupId': 'OG001', 'value': '6.97'}]}]},\n",
       "     {'title': 'Week 3 (N = 252, 245)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '22.62'},\n",
       "         {'groupId': 'OG001', 'value': '13.47'}]}]},\n",
       "     {'title': 'Week 4 (N = 246, 229)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '25.20'},\n",
       "         {'groupId': 'OG001', 'value': '17.90'}]}]},\n",
       "     {'title': 'Week 5 (N = 241, 226)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '28.22'},\n",
       "         {'groupId': 'OG001', 'value': '19.47'}]}]},\n",
       "     {'title': 'Week 6 (N = 244, 227)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '29.51'},\n",
       "         {'groupId': 'OG001', 'value': '22.91'}]}]},\n",
       "     {'title': 'Week 7 (N= 240, 216)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '30.42'},\n",
       "         {'groupId': 'OG001', 'value': '22.22'}]}]},\n",
       "     {'title': 'Week 8 (N = 236, 213)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33.05'},\n",
       "         {'groupId': 'OG001', 'value': '27.70'}]}]},\n",
       "     {'title': 'Week 9 (N = 232, 214)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '34.05'},\n",
       "         {'groupId': 'OG001', 'value': '26.17'}]}]},\n",
       "     {'title': 'Week 10 (N = 229, 212)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32.75'},\n",
       "         {'groupId': 'OG001', 'value': '26.42'}]}]},\n",
       "     {'title': 'Week 11 (N = 231, 211)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '34.20'},\n",
       "         {'groupId': 'OG001', 'value': '25.59'}]}]},\n",
       "     {'title': 'Week 12 (N = 227, 209)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '37.89'},\n",
       "         {'groupId': 'OG001', 'value': '26.79'}]}]},\n",
       "     {'title': 'Week 13 (N = 226, 204)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '35.84'},\n",
       "         {'groupId': 'OG001', 'value': '27.45'}]}]},\n",
       "     {'title': 'Week 14 (N = 223, 208)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '37.67'},\n",
       "         {'groupId': 'OG001', 'value': '29.81'}]}]},\n",
       "     {'title': 'Week 15 (N = 196, 187)',\n",
       "      'categories': [{'measurements': [{'groupId': 'OG000', 'value': '39.80'},\n",
       "         {'groupId': 'OG001', 'value': '34.22'}]}]}],\n",
       "    'analyses': [{'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 1',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1633',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '2.11',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.74',\n",
       "      'ciUpperLimit': '6.00'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 2',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0652',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.92',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.96',\n",
       "      'ciUpperLimit': '3.85'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 3',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0039',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '2.20',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.29',\n",
       "      'ciUpperLimit': '3.77'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 4',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0382',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.71',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.03',\n",
       "      'ciUpperLimit': '2.83'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 5',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0137',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.86',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.14',\n",
       "      'ciUpperLimit': '3.05'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 6',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0693',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.55',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.97',\n",
       "      'ciUpperLimit': '2.49'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 7',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0349',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.68',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.04',\n",
       "      'ciUpperLimit': '2.73'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 8',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1227',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.44',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.91',\n",
       "      'ciUpperLimit': '2.29'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 9',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0364',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.65',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.03',\n",
       "      'ciUpperLimit': '2.63'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 10',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0667',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.55',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.97',\n",
       "      'ciUpperLimit': '2.49'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 11',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0176',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.77',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.10',\n",
       "      'ciUpperLimit': '2.84'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 12',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0030',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '2.03',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.27',\n",
       "      'ciUpperLimit': '3.23'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 13',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0256',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.71',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.07',\n",
       "      'ciUpperLimit': '2.74'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 14',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.0314',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.66',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '1.05',\n",
       "      'ciUpperLimit': '2.64'},\n",
       "     {'groupIds': ['OG000', 'OG001'],\n",
       "      'groupDescription': 'Statistical analysis at Week 15',\n",
       "      'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY',\n",
       "      'pValue': '0.1889',\n",
       "      'statisticalMethod': 'Gen linear model-logistic link function',\n",
       "      'statisticalComment': 'Model terms include categorical: treatment, center, trauma type, week, and treatment-by-week interaction; and continuous: baselines mean pain score.',\n",
       "      'paramType': 'Odds Ratio (OR)',\n",
       "      'paramValue': '1.38',\n",
       "      'ciPctValue': '95',\n",
       "      'ciLowerLimit': '0.85',\n",
       "      'ciUpperLimit': '2.21'}]}]},\n",
       " 'adverseEventsModule': {'frequencyThreshold': '5',\n",
       "  'timeFrame': 'From Day -21 to Day 112 (week 16) i.e. from baseline until 1 day post last taper dose.',\n",
       "  'description': 'The adverse events reporting period was from the signing of the informed consent (at screening) throughout the study including 28 calendar days from the last dose of study medication.',\n",
       "  'eventGroups': [{'id': 'EG000',\n",
       "    'title': 'Pregabalin',\n",
       "    'description': 'Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase.',\n",
       "    'seriousNumAffected': 2,\n",
       "    'seriousNumAtRisk': 274,\n",
       "    'otherNumAffected': 75,\n",
       "    'otherNumAtRisk': 274},\n",
       "   {'id': 'EG001',\n",
       "    'title': 'Placebo',\n",
       "    'description': 'Participants randomized to receive placebo',\n",
       "    'seriousNumAffected': 7,\n",
       "    'seriousNumAtRisk': 265,\n",
       "    'otherNumAffected': 33,\n",
       "    'otherNumAtRisk': 265}],\n",
       "  'seriousEvents': [{'term': 'Atrial fibrillation',\n",
       "    'organSystem': 'Cardiac disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Haemorrhoids',\n",
       "    'organSystem': 'Gastrointestinal disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Urinary tract infection',\n",
       "    'organSystem': 'Infections and infestations',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Concussion',\n",
       "    'organSystem': 'Injury, poisoning and procedural complications',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Overdose',\n",
       "    'organSystem': 'Injury, poisoning and procedural complications',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Post procedural discharge',\n",
       "    'organSystem': 'Injury, poisoning and procedural complications',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Hypoglycaemia',\n",
       "    'organSystem': 'Metabolism and nutrition disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 2,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Lumbar spinal stenosis',\n",
       "    'organSystem': 'Musculoskeletal and connective tissue disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Headache',\n",
       "    'organSystem': 'Nervous system disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Hypoglycaemic seizure',\n",
       "    'organSystem': 'Nervous system disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Major depression',\n",
       "    'organSystem': 'Psychiatric disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Chronic obstructive pulmonary disease',\n",
       "    'organSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Pneumonia aspiration',\n",
       "    'organSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 0,\n",
       "      'numAffected': 0,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 1,\n",
       "      'numAffected': 1,\n",
       "      'numAtRisk': 265}]}],\n",
       "  'otherEvents': [{'term': 'Nausea',\n",
       "    'organSystem': 'Gastrointestinal disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 15,\n",
       "      'numAffected': 14,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 8,\n",
       "      'numAffected': 8,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Fatigue',\n",
       "    'organSystem': 'General disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 16,\n",
       "      'numAffected': 14,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 10,\n",
       "      'numAffected': 10,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Dizziness',\n",
       "    'organSystem': 'Nervous system disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 51,\n",
       "      'numAffected': 40,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 13,\n",
       "      'numAffected': 11,\n",
       "      'numAtRisk': 265}]},\n",
       "   {'term': 'Somnolence',\n",
       "    'organSystem': 'Nervous system disorders',\n",
       "    'sourceVocabulary': 'MedDRA version 18.1',\n",
       "    'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT',\n",
       "    'stats': [{'groupId': 'EG000',\n",
       "      'numEvents': 31,\n",
       "      'numAffected': 27,\n",
       "      'numAtRisk': 274},\n",
       "     {'groupId': 'EG001',\n",
       "      'numEvents': 10,\n",
       "      'numAffected': 9,\n",
       "      'numAtRisk': 265}]}]},\n",
       " 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False,\n",
       "   'restrictionType': 'OTHER',\n",
       "   'restrictiveAgreement': True,\n",
       "   'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.'},\n",
       "  'pointOfContact': {'title': 'Pfizer Clinical Trials.gov Call Center',\n",
       "   'organization': 'Pfizer, Inc',\n",
       "   'email': 'ClinicalTrials.gov_Inquiries@pfizer.com',\n",
       "   'phone': '1-800-718-1021'}}}"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "studies[0][\"resultsSection\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'miscInfoModule': {'versionHolder': '2024-04-05',\n",
       "  'removedCountries': ['Israel']},\n",
       " 'conditionBrowseModule': {'meshes': [{'id': 'D000009437',\n",
       "    'term': 'Neuralgia'}],\n",
       "  'ancestors': [{'id': 'D000010523',\n",
       "    'term': 'Peripheral Nervous System Diseases'},\n",
       "   {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "   {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "   {'id': 'D000010146', 'term': 'Pain'},\n",
       "   {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "  'browseLeaves': [{'id': 'M12381',\n",
       "    'name': 'Neuralgia',\n",
       "    'asFound': 'Neuropathic Pain',\n",
       "    'relevance': 'HIGH'},\n",
       "   {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "   {'id': 'M13432',\n",
       "    'name': 'Peripheral Nervous System Diseases',\n",
       "    'relevance': 'LOW'},\n",
       "   {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "   {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}],\n",
       "  'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "   {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "   {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       " 'interventionBrowseModule': {'meshes': [{'id': 'D000069583',\n",
       "    'term': 'Pregabalin'}],\n",
       "  'ancestors': [{'id': 'D000000700', 'term': 'Analgesics'},\n",
       "   {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "   {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "   {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "   {'id': 'D000000927', 'term': 'Anticonvulsants'},\n",
       "   {'id': 'D000002121', 'term': 'Calcium Channel Blockers'},\n",
       "   {'id': 'D000049990', 'term': 'Membrane Transport Modulators'},\n",
       "   {'id': 'D000045504',\n",
       "    'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "   {'id': 'D000077264', 'term': 'Calcium-Regulating Hormones and Agents'},\n",
       "   {'id': 'D000014151', 'term': 'Anti-Anxiety Agents'},\n",
       "   {'id': 'D000014149', 'term': 'Tranquilizing Agents'},\n",
       "   {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "   {'id': 'D000011619', 'term': 'Psychotropic Drugs'}],\n",
       "  'browseLeaves': [{'id': 'M476',\n",
       "    'name': 'Pregabalin',\n",
       "    'asFound': 'Pulse',\n",
       "    'relevance': 'HIGH'},\n",
       "   {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'},\n",
       "   {'id': 'M4246', 'name': 'Anticonvulsants', 'relevance': 'LOW'},\n",
       "   {'id': 'M5398', 'name': 'Calcium, Dietary', 'relevance': 'LOW'},\n",
       "   {'id': 'M5381', 'name': 'Calcium', 'relevance': 'LOW'},\n",
       "   {'id': 'M5384', 'name': 'Calcium Channel Blockers', 'relevance': 'LOW'},\n",
       "   {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "   {'id': 'M16905', 'name': 'Anti-Anxiety Agents', 'relevance': 'LOW'},\n",
       "   {'id': 'M14474', 'name': 'Psychotropic Drugs', 'relevance': 'LOW'}],\n",
       "  'browseBranches': [{'abbrev': 'ChanBlk', 'name': 'Channel Blockers'},\n",
       "   {'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "   {'abbrev': 'AntiConv', 'name': 'Anticonvulsants'},\n",
       "   {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "   {'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'},\n",
       "   {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "   {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}]}}"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "studies[0][\"derivedSection\"]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "studies[0][\"hasResults\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "ename": "MaxTriesExceededException",
     "evalue": "Cannot Fetch from Google Scholar.",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mMaxTriesExceededException\u001b[0m                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[2], line 11\u001b[0m\n\u001b[0;32m      8\u001b[0m scholarly\u001b[38;5;241m.\u001b[39muse_proxy(pg)\n\u001b[0;32m     10\u001b[0m \u001b[38;5;66;03m# Now search Google Scholar from behind a proxy\u001b[39;00m\n\u001b[1;32m---> 11\u001b[0m search_query \u001b[38;5;241m=\u001b[39m \u001b[43mscholarly\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msearch_pubs\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43mPerception of physical stability and center of mass of 3D objects\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[0;32m     12\u001b[0m scholarly\u001b[38;5;241m.\u001b[39mpprint(\u001b[38;5;28mnext\u001b[39m(search_query))\n\u001b[0;32m     14\u001b[0m \u001b[38;5;66;03m# you don't need to explicitly use the \"AND\" operator because including multiple words or phrases in a search query already implies a logical AND between them.\u001b[39;00m\n",
      "File \u001b[1;32md:\\Purdue\\Academics\\Spring\\Industry Practicum\\LLM-Marketing-agent\\ipvenv\\lib\\site-packages\\scholarly\\_scholarly.py:160\u001b[0m, in \u001b[0;36m_Scholarly.search_pubs\u001b[1;34m(self, query, patents, citations, year_low, year_high, sort_by, include_last_year, start_index)\u001b[0m\n\u001b[0;32m     97\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"Searches by query and returns a generator of Publication objects\u001b[39;00m\n\u001b[0;32m     98\u001b[0m \n\u001b[0;32m     99\u001b[0m \u001b[38;5;124;03m:param query: terms to be searched\u001b[39;00m\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    155\u001b[0m \n\u001b[0;32m    156\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[0;32m    157\u001b[0m url \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_construct_url(_PUBSEARCH\u001b[38;5;241m.\u001b[39mformat(requests\u001b[38;5;241m.\u001b[39mutils\u001b[38;5;241m.\u001b[39mquote(query)), patents\u001b[38;5;241m=\u001b[39mpatents,\n\u001b[0;32m    158\u001b[0m                           citations\u001b[38;5;241m=\u001b[39mcitations, year_low\u001b[38;5;241m=\u001b[39myear_low, year_high\u001b[38;5;241m=\u001b[39myear_high,\n\u001b[0;32m    159\u001b[0m                           sort_by\u001b[38;5;241m=\u001b[39msort_by, include_last_year\u001b[38;5;241m=\u001b[39minclude_last_year, start_index\u001b[38;5;241m=\u001b[39mstart_index)\n\u001b[1;32m--> 160\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m__nav\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msearch_publications\u001b[49m\u001b[43m(\u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32md:\\Purdue\\Academics\\Spring\\Industry Practicum\\LLM-Marketing-agent\\ipvenv\\lib\\site-packages\\scholarly\\_navigator.py:296\u001b[0m, in \u001b[0;36mNavigator.search_publications\u001b[1;34m(self, url)\u001b[0m\n\u001b[0;32m    288\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21msearch_publications\u001b[39m(\u001b[38;5;28mself\u001b[39m, url: \u001b[38;5;28mstr\u001b[39m) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m _SearchScholarIterator:\n\u001b[0;32m    289\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"Returns a Publication Generator given a url\u001b[39;00m\n\u001b[0;32m    290\u001b[0m \n\u001b[0;32m    291\u001b[0m \u001b[38;5;124;03m    :param url: the url where publications can be found.\u001b[39;00m\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    294\u001b[0m \u001b[38;5;124;03m    :rtype: {_SearchScholarIterator}\u001b[39;00m\n\u001b[0;32m    295\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[1;32m--> 296\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43m_SearchScholarIterator\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32md:\\Purdue\\Academics\\Spring\\Industry Practicum\\LLM-Marketing-agent\\ipvenv\\lib\\site-packages\\scholarly\\publication_parser.py:53\u001b[0m, in \u001b[0;36m_SearchScholarIterator.__init__\u001b[1;34m(self, nav, url)\u001b[0m\n\u001b[0;32m     51\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_pubtype \u001b[38;5;241m=\u001b[39m PublicationSource\u001b[38;5;241m.\u001b[39mPUBLICATION_SEARCH_SNIPPET \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m/scholar?\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m url \u001b[38;5;28;01melse\u001b[39;00m PublicationSource\u001b[38;5;241m.\u001b[39mJOURNAL_CITATION_LIST\n\u001b[0;32m     52\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_nav \u001b[38;5;241m=\u001b[39m nav\n\u001b[1;32m---> 53\u001b[0m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_load_url\u001b[49m\u001b[43m(\u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     54\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mtotal_results \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_get_total_results()\n\u001b[0;32m     55\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mpub_parser \u001b[38;5;241m=\u001b[39m PublicationParser(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_nav)\n",
      "File \u001b[1;32md:\\Purdue\\Academics\\Spring\\Industry Practicum\\LLM-Marketing-agent\\ipvenv\\lib\\site-packages\\scholarly\\publication_parser.py:59\u001b[0m, in \u001b[0;36m_SearchScholarIterator._load_url\u001b[1;34m(self, url)\u001b[0m\n\u001b[0;32m     57\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_load_url\u001b[39m(\u001b[38;5;28mself\u001b[39m, url: \u001b[38;5;28mstr\u001b[39m):\n\u001b[0;32m     58\u001b[0m     \u001b[38;5;66;03m# this is temporary until setup json file\u001b[39;00m\n\u001b[1;32m---> 59\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_soup \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_nav\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_get_soup\u001b[49m\u001b[43m(\u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     60\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_pos \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[0;32m     61\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_rows \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_soup\u001b[38;5;241m.\u001b[39mfind_all(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mdiv\u001b[39m\u001b[38;5;124m'\u001b[39m, class_\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mgs_r gs_or gs_scl\u001b[39m\u001b[38;5;124m'\u001b[39m) \u001b[38;5;241m+\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_soup\u001b[38;5;241m.\u001b[39mfind_all(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mdiv\u001b[39m\u001b[38;5;124m'\u001b[39m, class_\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mgsc_mpat_ttl\u001b[39m\u001b[38;5;124m'\u001b[39m)\n",
      "File \u001b[1;32md:\\Purdue\\Academics\\Spring\\Industry Practicum\\LLM-Marketing-agent\\ipvenv\\lib\\site-packages\\scholarly\\_navigator.py:239\u001b[0m, in \u001b[0;36mNavigator._get_soup\u001b[1;34m(self, url)\u001b[0m\n\u001b[0;32m    237\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_get_soup\u001b[39m(\u001b[38;5;28mself\u001b[39m, url: \u001b[38;5;28mstr\u001b[39m) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m BeautifulSoup:\n\u001b[0;32m    238\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"Return the BeautifulSoup for a page on scholar.google.com\"\"\"\u001b[39;00m\n\u001b[1;32m--> 239\u001b[0m     html \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_get_page\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43mhttps://scholar.google.com\u001b[39;49m\u001b[38;5;132;43;01m{0}\u001b[39;49;00m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mformat\u001b[49m\u001b[43m(\u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    240\u001b[0m     html \u001b[38;5;241m=\u001b[39m html\u001b[38;5;241m.\u001b[39mreplace(\u001b[38;5;124mu\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;130;01m\\xa0\u001b[39;00m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;124mu\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m \u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[0;32m    241\u001b[0m     res \u001b[38;5;241m=\u001b[39m BeautifulSoup(html, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mhtml.parser\u001b[39m\u001b[38;5;124m'\u001b[39m)\n",
      "File \u001b[1;32md:\\Purdue\\Academics\\Spring\\Industry Practicum\\LLM-Marketing-agent\\ipvenv\\lib\\site-packages\\scholarly\\_navigator.py:190\u001b[0m, in \u001b[0;36mNavigator._get_page\u001b[1;34m(self, pagerequest, premium)\u001b[0m\n\u001b[0;32m    188\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_get_page(pagerequest, \u001b[38;5;28;01mTrue\u001b[39;00m)\n\u001b[0;32m    189\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m--> 190\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m MaxTriesExceededException(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCannot Fetch from Google Scholar.\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "\u001b[1;31mMaxTriesExceededException\u001b[0m: Cannot Fetch from Google Scholar."
     ]
    }
   ],
   "source": [
    "from scholarly import scholarly\n",
    "from scholarly import ProxyGenerator\n",
    "\n",
    "# Set up a ProxyGenerator object to use free proxies\n",
    "# This needs to be done only once per session\n",
    "pg = ProxyGenerator()\n",
    "pg.FreeProxies()\n",
    "scholarly.use_proxy(pg)\n",
    "\n",
    "# you don't need to explicitly use the \"AND\" operator because including multiple words or phrases in a search query already implies a logical AND between them.\n",
    "query_terms = \"Neurogenic pain AND psychological distress\"\n",
    "\n",
    "# Search for publications containing the query_terms\n",
    "search_query = scholarly.search_pubs(query_terms)\n",
    "\n",
    "# Fetch a specified number of publications from the search results\n",
    "publications = []\n",
    "for i in range(1):  # Adjust the range to fetch more or fewer results\n",
    "    try:\n",
    "        pub = next(search_query)\n",
    "        publications.append(pub)\n",
    "    except StopIteration:\n",
    "        break\n",
    "\n",
    "# Example: Print the titles of the fetched publications\n",
    "for pub in publications:\n",
    "    print(pub['bib']['title'])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "ipvenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
